Launch HN: SafeBeat Rx (YC S21)- At-home ECG software to replace hospitalization
34M people have atrial fibrillation (AFib), the most common heart rhythm disorder in the world. It causes 1 in 4 strokes in people over 40 and increases the risk of death by 4x. Antiarrhythmic meds improve symptoms and save lives. Unfortunately, these pills can only be started during a 3+ day hospitalization because early drug trials showed <0.6% risk of causing sudden cardiac death. This can be prevented by ECG monitoring, but there hasn't been an alternative to hospitalization since the drugs were approved 30 years ago.
For low-risk patients, the risks of hospitalization outweigh the risk of medication side effects, and patients in underserved areas often don't even have access to hospitals. From a hospital/insurer perspective, each of these hospitalizations costs $17k and takes a hospital bed that would otherwise go to someone who actually needs hospital-level care. Because of unnecessary expenditures like this, AFib costs >$26B in the US alone, 75% of which is for hospitalizations.
As a cardiologist specializing in heart rhythm disorders, I regularly cared for patients who were stuck in the hospital just to start these oral pills. All I was doing for these folks (as a physician with >10 years of medical training!) was making a tiny measurement on a paper ECG with physical calipers to check for drug side effects. Given my engineering background, I knew we could develop software that automates this process. I also knew, as an AFib researcher presenting at international heart rhythm conferences, that this was a large market desperate for improvement. When COVID-19 brought telehealth to the forefront, it became clear that we should build a startup to solve this.
Our take-home kit combines FDA-approved wearable hardware devices with our ECG software that automates measurements, recommends drug dosing, and catches changes before they become heart attacks. Here’s a demo of our portal, which is a functional prototype that allows doctors to interact with our algorithm (and helps us get feedback on performance): https://drive.google.com/file/d/10iBo_EznZOQ_RHLiFzcGTnA-GER.... Doctors approve our algorithm’s measurements and dosing at every step for safety. Our interface aims for simplicity, based on what we wanted ourselves while treating patients.
We’ve done a 103 patient pilot study, which showed that our software successfully interpreted 100% of ECGs and could even replicate doctors’ clinical decisions. Our FDA path is short due to using existing FDA-cleared hardware, and we are seeking EUA (Emergency Use Authorization) during the pandemic. Some drugs tried on COVID-19 early in the pandemic caused people to die due to heart rhythm side effects. Our technology can prevent such deaths—not only from heart meds, but from 300+ meds that can cause sudden cardiac death, and thus require close ECG monitoring.
Insurers are incentivized to reimburse our kit, and hospitals want to preserve valuable beds for sicker patients. Because heart rhythm side effects are the #1 reason drugs are declined FDA approval, we also aim to partner with pharmaceutical companies testing new drugs. Our automated system to monitor heart rhythm safety while starting drugs can tap the giant market of drug safety trials.
We’re excited to share what we’ve been building and look forward to your thoughts!
71 comments
[ 7.2 ms ] story [ 132 ms ] threadDo you have a link to the study? Isn’t that a relatively low number of patients to validate against?
Congratulations on the launch, and I wish you well, and hope it is of great use to thousands!
> existing FDA-cleared hardware Can you please link to this?
Or perhaps more to the point - the problem you mention in OP seems, as described, like it's already solved by Kardia, what was missing that you had to build?
Now, how do I also get your software that will work with this hardware?
> The 510(k) Clearance process is one of two ways by which a medical device manufacturer can obtain approval from the Food and Drug Administration, although legally, a device clearance under this section is not a true “approval.” 510(k) Clearance simply gives the company permission to market its product, based on comparison to a “predicate” [previously approved] device.[1]
Basically, If a somewhat similar device is already on the market, the FDA will clear the new device for the market.
[0] https://www.fda.gov/medical-devices/device-approvals-denials...
[1] https://www.levinlaw.com/fda-510k
- What makes you "better" than your competitors, perhaps especially those of your competitors with substantially deeper pockets than you ? (e.g. Apple Watch which also has "ECG" functionality).
- Building on the above, how's the prior art looking on the patents ?
- Finally, general cynicism on "home ECG".... clinical evaluation is 12 lead ECG. Can you really get away with substantially less input ? (Garbage In - Garbage Out).
There are single lead chest ECG patches used for specific diagnostic reasons. Zio patch is one common device used. [0]
[0] https://www.irhythmtech.com/patients/how-it-works
If patent filings are a guide[1], Apple are aware and have been investigating options for user-friendly additional sensors elsewhere on the body.
Whether it comes to market is another matter, of course.
[1] http://patft1.uspto.gov/netacgi/nph-Parser?patentnumber=1108...
So, I think this is a great idea.
She is currently waiting for an ablation, which was a close call vs leaving her in it, but she wanted to try it.
We have a rudimentary, un-inspirational website: http://www.koalasleeve.com/
Just filed the patents.
I am genuinely curious to see the breakdown of where that money goes
On the outpatient facility they would have charged $1100.
Typically at my institution we load first and cardiovert later if needed. How is that handled in your system?
Also, what is the clinicaltrials.gov registration for your completed Phase I?
Phase I Software validation doesn't require clinicaltrials.gov registration, but our Phase II trial will be per FDA!
Also, I didn't realize that Phase I trials didn't have to be registered on clinicaltrials.gov! But you're right, they're specifically exempted[1].
1 = https://clinicaltrials.gov/ct2/manage-recs/fdaaa#WhichTrials...
The amount of hassle and anxiety this will save me is impressive on its own, but so to is the ability to have a normal lifestyle (such as going out for a drink) without having to worry about whether or not I’m always in range of a hospital that I want to spend 3 days in if I’m unlucky
Thank you and good luck!
On a related note, I've been thinking about building something similar for personal use using one of those audrino based ECGs (just recording and then finding anomalies). Never got the time though.
I've already validated that the idea would be useful. There's a potential annual patient population of around 7 million people in the US. Even at 10% adoption, that could be revenue of $100-200M with a conservative guesstimate profit margin of 10-20% at that level (variable costs are low, so that should be higher as it scales). Current price of testing is high enough that I think this device could fit into that range or under cut it, with a multifaceted improvement to patient experience. A brief search turned up no competitors.
Now I'm trying to decide if I should spend the money to build a prototype and file a provisional patent or not. It depends on exactly how expensive and lengthy the approval process is, how HIPPA might or might not apply, etc. The type of software it will require will also be a challenge for me since I've never made anything like this.
I also have an lvad and spend a lot of time in the hospital taking quite a few medications
It seems fair to summarize this as a "smart(er) Holter monitor".
I wonder whether there exist some Holter monitors that could be made more functional with just a firmware reprogramming job. You really need interfacing though: BT, Wi-Fi, ...
I hope your service makes ECG more accessible to identify heart diseases earlier.